EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Redefining Omalizumab Discontinuation in Chronic Spontaneous Urticaria: The Value of Optimization and Predictive Factors of Relapse. A 52-Week Multicenter Study

J Ceravalls, A M Giménez-Arnau, V Expósito-Serrano, N Fernández Chico, A Lara Moya, I Bielsa, P Ribó, B Mascaró-Hereza, M Bonfill-Ortí, J Spertino, E Serra, C Baliu-Piqué und 1 weitere

Actas Dermo-Sifiliográficas · 2025-07 · 116 (7) · 675-683

DOI: 10.1016/j.ad.2024.08.014 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Actas Dermo-Sifiliográficas, 2025-07. Verfasst von J Ceravalls und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital Universitari Sagrat Cor, Grupo QuirónSalud, Barcelona, Catalonia, Spain. Electronic address: drceravalls@gmail.co…. Hauptthemen laut MEDLINE: Omalizumab, Chronic Urticaria, Anti-Allergic Agents, Withholding Treatment. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Patients with chronic spontaneous urticaria frequently relapse after discontinuing omalizumab and require its reintroduction. Although prior optimization might reduce recurrences, there is scarce evidence on this issue. Moreover, predictors of relapse have been identified in non-optimized patients before suspension. METHODS: We conducted a multicenter retrospective study with patients who discontinued omalizumab after optimization with a 12-month follow-up. Univariate and multivariate (tree classification method and Cox regression) analyses were performed. RESULTS: A total of 131 patients were included, 32.8% of whom relapsed after 12 months. Relapsed patients had longer disease duration (24.00 vs 11.00 months; p=0.032), quicker response to standard dosage (1.00 vs. 3.00 months; p=0.014), fewer complete responses pre-optimization (83.70% vs 95.50%; p=0.023), and shorter treatment duration at 300mg/4 weeks (6 vs 7 months; p=0.035). Multivariate analysis revealed that patients with low baseline C-reactive protein (CRP) and total immunoglobulin E (IgE) who underwent prolonged treatment were more likely to maintain a sustained remission at 12 months. CONCLUSION: Optimization seems to reduce the relapse rate after discontinuation. The most relevant factors for recurrence are associated with the duration of treatment at different doses of omalizumab, along with the baseline CRP and total IgE levels. To minimize relapse after suspension, a 12-month treatment regimen at 300mg/4 weeks followed by an 18-month dose tapering is proposed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OmalizumabChronic UrticariaAnti-Allergic AgentsWithholding TreatmentHumansRetrospective StudiesMaleFemaleRecurrenceAdultMiddle AgedImmunoglobulin EC-Reactive ProteinTime FactorsAged

Stichwörter der Autor:innen

AlgorithmAlgoritmoBiomarcadoresBiomarkersChronic spontaneous urticariaDiscontinuaciónDiscontinuationOmalizumabOptimizaciónOptimizationRecaídaRelapseUrticaria crónica espontánea

Substanzen

OmalizumabAnti-Allergic AgentsImmunoglobulin EC-Reactive Protein

Autor:innen und Institutionen

  • Department of Dermatology, Hospital Universitari Sagrat Cor, Grupo QuirónSalud, Barcelona, Catalonia, Spain. Electronic address: drceravalls@gmail.com.
  • Department of Dermatology, Hospital de Mar Research Institute, Universitat Pompeu Fabra, Barcelona, Catalonia, Spain.
  • Department of Dermatology, Consorci Sanitari Parc Taulí, Sabadell, Catalonia, Spain.
  • Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Catalonia, Spain.
  • Department of Allergology, Hospital Clínic, Universitat de Barcelona, Catalonia, Spain.
  • Department of Dermatology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Catalonia, Spain.

Zitieren

APA

Ceravalls, J., Giménez-Arnau, A. M., Expósito-Serrano, V., Fernández Chico, N., Lara Moya, A., Bielsa, I., Ribó, P., Mascaró-Hereza, B., Bonfill-Ortí, M., Spertino, J., Serra, E., Baliu-Piqué, C., & Melé-Ninot, G. (2025). Redefining Omalizumab Discontinuation in Chronic Spontaneous Urticaria: The Value of Optimization and Predictive Factors of Relapse. A 52-Week Multicenter Study. Actas Dermo-Sifiliográficas. https://doi.org/10.1016/j.ad.2024.08.014

Vancouver

Ceravalls J, Giménez-Arnau AM, Expósito-Serrano V, Fernández Chico N, Lara Moya A, Bielsa I, et al. Redefining Omalizumab Discontinuation in Chronic Spontaneous Urticaria: The Value of Optimization and Predictive Factors of Relapse. A 52-Week Multicenter Study. Actas Dermo-Sifiliográficas. 2025. doi:10.1016/j.ad.2024.08.014

BibTeX
@article{Ceravalls2025,
  author = {Ceravalls, J and Giménez-Arnau, A M and Expósito-Serrano, V and Fernández Chico, N and Lara Moya, A and Bielsa, I and Ribó, P and Mascaró-Hereza, B and Bonfill-Ortí, M and Spertino, J and Serra, E and Baliu-Piqué, C and Melé-Ninot, G},
  title = {Redefining Omalizumab Discontinuation in Chronic Spontaneous Urticaria: The Value of Optimization and Predictive Factors of Relapse. A 52-Week Multicenter Study},
  journal = {Actas Dermo-Sifiliográficas},
  year = {2025},
  doi = {10.1016/j.ad.2024.08.014}
}
Kostenlos starten →